Q1 2026 Heartbeam Inc Earnings Call Transcript
Key Points
- HeartBeam Inc (BEAT) signed its first commercial partnership in Q1 with ClearCardio, establishing a presence in key markets like New York City, Dallas, and South Florida.
- The company has developed a portable, cable-free ECG system that synthesizes a 12-lead ECG, receiving two FDA clearances for arrhythmia assessment.
- HeartBeam Inc (BEAT) initiated a strategic collaboration with Mount Sinai to develop next-generation AI algorithms for heart attack detection and personalized cardiac assessment.
- The company completed a working prototype of its 12-lead patch and initiated a pilot study focused on ischemia detection, targeting a $2 billion market.
- HeartBeam Inc (BEAT) strengthened its financial position with an $11.5 million financing, providing a cash runway to advance into the next phase of growth.
- HeartBeam Inc (BEAT) reported a net loss of $4.7 million for Q1 2026, with net cash used in operating activities amounting to $3.6 million.
- The company is still in the early stages of commercialization, with revenue generation not being the primary focus for the first half of 2026.
- HeartBeam Inc (BEAT) faces challenges in scaling its operations, requiring careful management of cash and dilution to maintain a low-cost profile.
- The company is dependent on successful partnerships and adoption within anchor accounts to achieve its revenue and growth targets.
- HeartBeam Inc (BEAT) is still in the process of validating its premium value proposition and refining its systems and processes for broader adoption.
Greetings, and welcome to the HeartBeam first quarter 2026 financial results conference call. (Operator Instructions)
As a reminder, this conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that the statements made on the call and webcast may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially.
You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in the light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our prediction. You should also review our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
